Clinical trials: ADD/ADHD
Attention Deficit Hyperactivity Disorder
Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
The objective of this study was to establish that an optimal dose of Quillivant XR oral suspension would result in a significant reduction in signs and symptoms of ADHD compared to placebo treatment in pediatric patients ages…
- Trial name
- NCT00904670
- Testing
- Quillivant Oral Suspension XR
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Pfizer
Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).
- Trial name
- NCT07759154
- Testing
- Centanafadine XR
- Where
- 16 sites in United States
- Volunteers
- 80 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents
Comparison of the effect of Atomoxetine and psychoeducation with placebo and psychoeducation after 10 weeks of treatment
- Trial name
- NCT00191542
- Testing
- Atomoxetine
- Where
- 9 sites in Sweden
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
ADHD, Depression Disorders
Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device
The study aims to verify if the Gaize ocular device can effectively identify eye movements indicative of prescribed psychotropic medication usage by employing Drug Recognition Expert (DRE) testing protocols within a controlled…
- Conditions
- ADHD, Depression Disorders, Mood Disorders, Anxiety Disorder Generalized
- Trial name
- Rx Meds Gaize (NCT07389473)
- Testing
- Prescription Psychotropic Medications
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Gaize
Attention Deficit Hyperactivity Disorder
Neurophysiological Attention Test (NAT) for Objective Assessment of Adult ADHD
The purpose of this study is to refine a new assessment tool for Attention Deficit/Hyperactivity Disorder (ADHD) and then to test its validity (i.e. ability to discriminate between individuals with ADHD and healthy controls.
- Trial name
- NAT-II (NCT02756286)
- Testing
- NAT electroencephalography (EEG) test
- Where
- 3 sites in United States
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- Think Now Incorporated
Attention Deficit Hyperactivity Disorder
Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD
The purpose of this protocol is to investigate the acute treatment efficacy, safety, and tolerability of atomoxetine on a once-daily dosing strategy in Taiwanese children and adolescents with ADHD.
- Trial name
- NCT00485459
- Testing
- Atomoxetine Hydrochloride
- Where
- Taiwan
- Volunteers
- 106 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder
The purpose of this study is to determine the long-term efficacy and safety of KAPVAY™ (clonidine hydrochloride) extended-release in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
- Trial name
- NCT01439126
- Testing
- clonidine hydrochloride
- Volunteers
- 135 people
- Sponsor
- Concordia Pharmaceuticals Inc., Barbados
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety and effectiveness of NRP104 administered as a daily morning dose (30, 50, and 70mg/day) compared to placebo in adults (18-55 years of age inclusive) diagnosed with moderate to…
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
- Trial name
- NCT00334880
- Testing
- NRP104
- Where
- 48 sites in United States
- Volunteers
- 420 people
- Sponsor
- New River Pharmaceuticals
Attention-Deficit/Hyperactivity Disorder
Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 in adult ADHD patients
- Trial name
- NCT04143217
- Testing
- SPN-812
- Where
- 38 sites in United States
- Volunteers
- 159 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Stroke, TBI
Characterization of the DELPhI System in Assessing Brain's Functionality in Different Neurological Disorders
We use Transcranial magnetic stimulation (TMS), combined with simultaneous registration of electroencephalograph (EEG),for examining human cortical functionality.
- Conditions
- Stroke, TBI, Fibromyalgia, PDD
- Trial name
- NCT03832413
- Testing
- DELPhI (TMS-EEG analysis)
- Where
- Israel
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience
Oppositional Defiant Disorder, Conduct Disorder
Integrated Smart Speaker Promoting Positive Parenting Among Caregivers of Youth With Challenging Behaviors
This project will develop and evaluate the feasibility of an integrated smart speaker and mobile/web-based application, "FamilyNet" (FN) to assist parents in implementing empirically supported behavioral parenting strategies to…
- Trial name
- FamilyNet (NCT05535387)
- Testing
- FamilyNet smart speaker/mobile application
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (process by which JNJ-31001074 is absorbed, distributed, metabolized, and eliminated by the body) after a single dose of JNJ-31001074.
- Trial name
- NCT00890240
- Testing
- JNJ-31001074
- Volunteers
- 18 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Insomnia, Attention Deficit Hyperactivity Disorder
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
- Trial name
- NCT00857220
- Testing
- eszopiclone
- Where
- 89 sites in United States
- Volunteers
- 304 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Hyperactivity Disorder
Software Treatment for Actively Reducing Severity of ADHD in Adolescents (STARS-ADHD-Adolescents)
The purpose of this study is to evaluate the effects of videogame-like digital therapy on attentional functioning and symptoms in adolescents ages 13-17 diagnosed with ADHD
- Trial name
- NCT04897074
- Testing
- AKL-T01
- Where
- 14 sites in United States
- Volunteers
- 165 people
- Sponsor
- Akili Interactive Labs, Inc.
Attention Deficit Hyperactivity Disorder
Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder
The purpose of this study is to assess the efficacy, the quality of life, and the safety of multiple dosing atomoxetine in Asian adult subjects with attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT00962104
- Testing
- Atomoxetine
- Where
- 24 sites in Japan, South Korea and 1 more
- Volunteers
- 391 people
- Sponsor
- Eli Lilly and Company
Naltrexone, Methylphenidate Abuse
Study for Naltrexone on the Abuse Potential of Methylphenidate
The current abuse liability study aims to assess the potential for co-administration of naltrexone (NTX) to reduce the abuse potential of methylphenidate (MPH).
- Trial name
- NCT03769064
- Testing
- Methylphenidate 60 mg, Treatment Phase Sequence 4213, Treatment Phase Sequence 2134
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Avekshan LLC
Attention Deficit/Hyperactivity Disorder
International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder
The aim of the iSPOT-A study is to: 1. identify brain, genetic and cognitive markers of Attention Deficit/Hyperactivity Disorder, and 2.
- Trial name
- NCT00863499
- Testing
- Short Acting Methylphenidate, Long Acting Methylphenidate
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 1,344 people, healthy volunteers welcome
- Sponsor
- BRC Operations Pty. Ltd.
ADHD, Comorbid Alcohol Abuse
Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse
Atomoxetine Treatment of Adults with ADHD and Comorbid Alcohol Abuse
- Trial name
- NCT00190957
- Testing
- Atomoxetine
- Where
- 15 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- Eli Lilly and Company
ADHD
Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD
- Trial name
- NCT00501293
- Testing
- Methylphenidate Transdermal System
- Where
- 32 sites in United States
- Volunteers
- 163 people
- Sponsor
- Noven Therapeutics
Attention Deficit Hyperactivity Disorder, Comorbid Social Anxiety Disorder
Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder
To investigate the effect of atomoxetine hydrochloride in treating adults who have attention deficit hyperactivity disorder with comorbid social anxiety disorder
- Trial name
- NCT00190879
- Testing
- Atomoxetine hydrochloride
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 440 people
- Sponsor
- Eli Lilly and Company